IQ-AI Limited "Gad Free" Imaging Update (1278N)

TIDMIQAI

RNS Number : 1278N

IQ-AI Limited

28 January 2021

IQ-AI Ltd

("IQ-AI" or the "Company")

"Gad Free" Imaging Update

IQ-AI continues to advance its Artificial Intelligence (AI) model for generating simulated "with contrast" images using images acquired without any contrast agent. Testing performed since the Company's last update has led to further refinements and improvements to the model. The simulated images generated using the AI model now very closely mimic actual, with contrast, images as shown here: https://imagingbiometrics.com/rns/ng1.png

The Company will now present full datasets of images to a select team of neuro radiologists who will qualitatively assess the quality of the simulated output images. Further validation includes a quantitative, voxel-wise, statistical comparison to understand how closely the model's simulated results match real world images. Finally, the model will be deployed to multiple sites to test on actual clinical data necessary for regulatory clearance.

Trevor Brown CEO said "Qualitatively, as illustrated in the link above, the recent improvements are so remarkable that "wow" is the only word which seems appropriate. We will continue to update shareholders on this important project as developments unfold."

The Directors of the Company accept responsibility for the contents of this announcement.

-ENDS-

For further information, please contact:

 
 IQ-AI Limited 
  Trevor Brown/Vinod Kaushal/Qu Li 
  Tel: [phone] 
---------------------------------------------------------- 
 Peterhouse Capital Limited (Financial Adviser and Broker) 
  Lucy Williams/Heena Karani 
  Tel: [phone] 
---------------------------------------------------------- 
 

ABOUT Imaging Biometrics , LLC

Imaging Biometrics(R), a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

STRPPUCGGUPGGBM

(END) Dow Jones Newswires

January 28, 2021 02:00 ET (07:00 GMT)